The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Approval is based on results from the phase 3 OASIS 4 clinical trial
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
